Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study

被引:2
|
作者
Dicitore, Alessandra [1 ]
Gaudenzi, Germano [2 ]
Carra, Silvia [3 ]
Cantone, Maria Celeste [2 ]
Oldani, Monica [2 ]
Saronni, Davide [1 ]
Borghi, Maria Orietta [4 ,5 ]
Grotteschi, Jacopo [1 ]
Persani, Luca [1 ,3 ]
Vitale, Giovanni [1 ,2 ]
机构
[1] Univ Milan, Dept Med Biotechnol & Translat Med, I-20122 Milan, Italy
[2] Ist Auxol Italiano, IRCCS, Lab Geriatr & Oncol Neuroendocrinol Res, Milan I-20145, Italy
[3] Ist Auxol Italiano, IRCCS, Lab Endocrine & Metab Res, I-20145 Milan, Italy
[4] Univ Milan, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy
[5] Ist Auxol Italiano, IRCCS, Expt Lab Immuno Rheumatol, I-20145 Milan, Italy
关键词
lung carcinoid; tyrosine kinase inhibitors; axitinib; cell cycle; apoptosis; zebrafish; tumor xenograft; ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; PHASE-II; NEUROENDOCRINE TUMORS; MICROVASCULAR DENSITY; ENDOCRINE TUMORS; OPEN-LABEL; ANGIOGENESIS; EXPRESSION; SUNITINIB;
D O I
10.3390/cancers15225375
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Lung carcinoids (LCs) are categorized as low- and intermediate-grade neuroendocrine tumors. Surgery is effective for localized LCs with a favorable prognosis. However, there is a pressing need for new treatments for unresectable and metastatic LCs. This study explored the potential antitumor effects of axitinib using both in vitro (immortalized cell lines) and in vivo (zebrafish) LC models. Axitinib demonstrated significant antitumor activity by reducing cell viability, inducing cell cycle arrest, and promoting cell death. Moreover, axitinib had a notable impact on crucial processes in tumor progression, including tumor-induced angiogenesis and invasiveness.Abstract Lung carcinoids (LCs) comprise well-differentiated neuroendocrine tumors classified as typical (TCs) and atypical (ACs) carcinoids. Unfortunately, curative therapies remain elusive for metastatic LCs, which account for 25-30% of cases. This study evaluated the antitumor activity of axitinib (AXI), a second-generation tyrosine kinase inhibitor selectively targeting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3) in human lung TC (NCI-H727, UMC-11, NCI-H835) and AC (NCI-H720) cell lines. In vitro and in vivo (zebrafish) assays were performed following AXI treatment to gather several read-outs about cell viability, cell cycle, the secretion of proangiogenic factors, apoptosis, tumor-induced angiogenesis and migration. AXI demonstrated relevant antitumor activity in human LC cells, with pronounced effects observed in UMC-11 and NCI-H720, characterized by cell cycle perturbation and apoptosis induction. AXI significantly hindered tumor induced-angiogenesis in Tg(fli1a:EGFP)y1 zebrafish embryos implanted with all LC cell lines and also reduced the invasiveness of NCI-H720 cells, as well as the secretion of several proangiogenic factors. In conclusion, our study provides initial evidence supporting the potential anti-tumor activity of AXI in LC, offering a promising basis for future investigations in mammalian animal models and, eventually, progressing to clinical trials.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Carcinoids among multiple lung tumorlets: Carcinoids or aggregates of tumorlets?
    Kaseda, Kaoru
    Izumi, Yotaro
    Hayashi, Yuichiro
    Goto, Taichiro
    Ohtsuka, Takashi
    Kohno, Mitsutomo
    PATHOLOGY INTERNATIONAL, 2014, 64 (02) : 91 - 93
  • [42] PEPTIDE RECEPTOR RADIONUCLIDE THERAPY IN LUNG CARCINOIDS: A BICENTER STUDY
    Zidan, L.
    Iravani, A.
    Oleinikov, K.
    Ben-Haim, S.
    Gross, D. J.
    Meirovitz, A.
    Maimon, O.
    Akhurst, T.
    Michael, M.
    Hicks, R. J.
    Grozinsky-Glasberg, S.
    Kong, G.
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 25 - 26
  • [43] Treatment of metastatic lung carcinoids
    Granberg, D
    Eriksson, B
    Welin, S
    Öberg, K
    Skogseid, B
    ENDOCRINE-RELATED CANCER, 2003, 10 (04) : 510 - 510
  • [44] The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer
    Dredge, K.
    Kink, J. A.
    Johnson, R. M.
    Bytheway, I.
    Marton, L. J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 65 (01) : 191 - 195
  • [45] The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer
    K. Dredge
    J. A. Kink
    R. M. Johnson
    I. Bytheway
    L. J. Marton
    Cancer Chemotherapy and Pharmacology, 2009, 65 : 191 - 195
  • [46] Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study
    Hui, Edwin P.
    Ma, Brigette B. Y.
    Loong, Herbert H. F.
    Mo, Frankie
    Li, Leung
    King, Ann D.
    Wang, Ki
    Ahuja, Anil T.
    Chan, Charles M. L.
    Hui, Connie W. C.
    Wong, Chi H.
    Chan, Anthony T. C.
    CLINICAL CANCER RESEARCH, 2018, 24 (05) : 1030 - 1037
  • [47] THE TYPICAL PICTURE OF LUNG CARCINOIDS
    HEITZ, M
    WOODTLI, W
    WIDMER, A
    GRAUER, W
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1986, : 30 - 30
  • [48] Antitumor Efficacy of Temozolomide in Patients with Metastatic Pulmonary Carcinoids
    Roufai, Bello D.
    Planchard, D.
    Walter, T.
    Berdelou, A.
    Guigay, J.
    Souquet, P. J.
    Mercier, O.
    Malka, D.
    Hervieu, V
    Leboulleux, S.
    Borget, I
    Scoazec, J. Y.
    Lombard-Bohas, C.
    Ducreux, M.
    Baudin, E.
    NEUROENDOCRINOLOGY, 2016, 103 : 65 - 65
  • [49] Antitumor activity of treosulfan in human lung carcinomas
    KopfMaier, P
    Sass, G
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 37 (03) : 211 - 221
  • [50] Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models
    Mcdowell, H. P.
    Meco, D.
    Riccardi, A.
    Tanno, B.
    Berardi, A.
    Raschella, G.
    Riccardi, R.
    Riccardi, R.
    Dominici, C.
    EJC SUPPLEMENTS, 2006, 4 (12): : 134 - 134